The results of the experiments shown in Fig. S6E demonstrated that intramarrow injection of AAV-MYDGF decreased the liver index, alleviated hepatic steatosis, decreased liver TG levels, decreased lipogenesis, reduced inflammation (Fig. 3A–I), and improved metabolic profiles (Fig. S7, Table S6), especially in KO mice. Here, MYDGF is linked to fatty liver disease.